Intellia's Lonvo-z Shows 89-91% Attack Reduction in Phase 3, Shares Climb 13%
NTLA sits 82% above its 52-week low of $7.95.
Summary
Intellia's gene-editing therapy, lonvo-z, demonstrated highly positive additional Phase 3 results for hereditary angioedema, reducing monthly attacks by 89% and severe attacks by 91%. This strong efficacy and favorable safety profile sent shares up 13%. The news follows earlier reports and an 8-K filing today detailing these results, which were initially anticipated in April. These results significantly de-risk the drug, and the company anticipates regulatory approval and a U.S. launch in the first half of 2027.
At the time of this announcement, NTLA was trading at $14.43 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $7.95 to $28.25. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.